Rebuild the knee,
don’t replace it.
Osteoarthritis has no cure. Yet.
It wears away the cartilage that cushions our joints, and with it, the everyday movements we take for granted. Today, patients choose between short-lived pain relief and joint replacement surgery. In between, there is nothing.
- 600M+
- people live with osteoarthritis worldwide
- 1B
- expected to be living with it by 2050
- 7 in 10
- cases affect the knee
- 0
- approved drugs that slow its progression
One injection. Three stages of care.
SYNARCH is an injectable hydrogel that the orthopedic surgeon applies in the clinic, with no operating room. It is designed to keep working long after the injection.
Relieve, Days
Lubricates the joint and eases pain, because patients need to feel better now.
Reduce inflammation, Weeks
Releases its therapy steadily, right where the damage is, to slow cartilage breakdown.
Regenerate, Months
Helps the joint’s own cells produce new cartilage again.
- Outpatient procedure
- No surgery
- Followed up with ultrasound in the clinic
Remains. Rejuvenates. Rebuilds.
Most knee injections wash out of the joint within hours or days. SYNARCH is a hydrogel built to stay and work where it is needed.
Who we are
The minds building the arch
Four founders bringing together biotechnology, bioengineering and chemistry to give osteoarthritis patients a better option.
Guided by
SYNARCH grows with the support of people who know the clinic, the lab and the market.
Incubated at Nucleate Genesis
Verónica Sotomayor
Biotech strategic advisor. Co-founder, SZeta Partners
Mariano Ballester, MD
Orthopedic surgeon, arthroscopy and knee specialist
Braian Aranda
B.S. in Economics, Finance
Thomas Huggias
B.S. in Software Architecture
Soledad Belluzo
PhD in Chemistry. Tissue Engineering and Biomaterials Expert
Get in touch
Investors, clinicians and partners: we would love to hear from you.